# Samyang Biopharmaceuticals Corporation trials: 30 (2026)

ClinicalTrials.gov lists 30 trials with Samyang Biopharmaceuticals Corporation as lead sponsor, 3 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Samyang Biopharmaceuticals Corporation: 30 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/samyang-biopharmaceuticals-corporation

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 30
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 30, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 12, 2026 | NCT07467239 | A Prospective Clinical Investigation of DMFI300 for Treating Nasolabial Folds | Samyang Biopharmaceuticals Corporation | Not applicable | Recruiting | Nasolabial Folds, Wrinkles | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07467239) |
| December 18, 2025 | NCT07292779 | A Prospective Clinical Investigation of DMFI150 for Treating Nasolabial Folds | Samyang Biopharmaceuticals Corporation | Not applicable | Recruiting | Nasolabial Folds, Wrinkles | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07292779) |
| May 8, 2025 | NCT06961448 | A Study in Adults Evaluating Polycaprolactone Microsphere Filler for Treatment of Moderate to Severe Nasolabial Folds | Samyang Biopharmaceuticals Corporation | Not applicable | Not yet recruiting | Nasolabial Fold Correction | 208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06961448) |
| May 7, 2024 | NCT06402058 | A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement | Samyang Biopharmaceuticals Corporation | Not applicable | Unknown | Crow's Feet Lines | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06402058) |
| March 6, 2024 | NCT06295172 | A Study Comparing Lafullen15 and Lafullen for Temporary Nasolabial Fold Improvement | Samyang Biopharmaceuticals Corporation | Not applicable | Unknown | Nasolabial Folds | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06295172) |
| October 23, 2023 | NCT06093321 | A Study Comparing SYB PDO Thread and MINT Lift® for Temporary Nasolabial Fold Improvement | Samyang Biopharmaceuticals Corporation | Not applicable | Unknown | Nasolabial Folds | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06093321) |
| December 12, 2022 | NCT05645809 | Clinical Trial to Evaluate the Safety and Efficacy of MONOFIX® PGCL Suture in Laparoscopic Surgery | Samyang Biopharmaceuticals Corporation | Not applicable | Unknown | Laparoscopic Hysterectomy | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05645809) |
| January 26, 2022 | NCT05207514 | Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer | Samyang Biopharmaceuticals Corporation | Phase 3 | Terminated | Breast Cancer | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05207514) |
| August 26, 2019 | NCT04066335 | Study to Evaluate the Safety of Nanoxel M Inj. | Samyang Biopharmaceuticals Corporation | Observational | Unknown | Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Ovarian Cancer, Head and Neck Cancer, Gastric Cancer... | 1,498 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04066335) |
| April 30, 2019 | NCT03932045 | A Study to Evaluate the Safety and Efficacy of SYB Filler(SF-01) in the Correction of Nasolabial Folds | Samyang Biopharmaceuticals Corporation | Not applicable | Completed | Nasolabial Folds | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03932045) |
| September 17, 2018 | NCT03674060 | Study to Compare Pharmacokinetic Property of SYO-1644 Tab. and Nexavar Tab. in Healthy Male Volunteers | Samyang Biopharmaceuticals Corporation | Phase 1 | Completed | Healthy, Male | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03674060) |
| July 5, 2017 | NCT03208218 | Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers | Samyang Biopharmaceuticals Corporation | Phase 1 | Completed | Healthy, Male | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03208218) |
| December 5, 2016 | NCT02982395 | Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC | Samyang Biopharmaceuticals Corporation | Phase 3 | Terminated | Non Muscle Invasive Bladder Cancer | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02982395) |
| April 15, 2016 | NCT02739633 | Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas | Samyang Biopharmaceuticals Corporation | Phase 2 | Unknown | Recurrent Adenocarcinoma of the Pancreas, Metastatic Adenocarcinoma of the Pancreas | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02739633) |
| April 15, 2016 | NCT02739529 | Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic Cancer | Samyang Biopharmaceuticals Corporation | Phase 1 | Unknown | Gynecologic Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02739529) |
| December 28, 2015 | NCT02639858 | Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC | Samyang Biopharmaceuticals Corporation | Phase 2 | Unknown | Head and Neck Squamous Cell Carcinoma | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02639858) |
| December 19, 2014 | NCT02320643 | A Pilot Study to Investigate the Efficacy of Partially Absorbable Mesh in Patients With Pelvic Organ Prolapsed | Samyang Biopharmaceuticals Corporation | Not applicable | Completed | Pelvic Organ Prolapse | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02320643) |
| October 24, 2014 | NCT02274610 | Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid Cancer | Samyang Biopharmaceuticals Corporation | Phase 1 | Completed | Solid Tumor | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02274610) |
| August 29, 2014 | NCT02228928 | Study of Capsaicin Patch for the Management of Peripheral Neuropathic Pain | Samyang Biopharmaceuticals Corporation | Phase 1/2 | Completed | Peripheral Nerve Injury, Postherpetic Neuralgia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02228928) |
| June 13, 2013 | NCT01877122 | Comparative Study of Safety and Efficacy of Heavyweight and Partially Absorbable Mesh in Inguinal Hernia Repair | Samyang Biopharmaceuticals Corporation | Phase 4 | Completed | Hernia, Inguinal | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01877122) |
| August 6, 2012 | NCT01657201 | Study to Evaluate the Pharmacokinetic Properties of SYP-1018 (Voriconazole-loaded PNP) and Voriconazole (Vfend) | Samyang Biopharmaceuticals Corporation | Phase 1 | Completed | Systemic Mycotic Infection | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01657201) |
| January 6, 2012 | NCT01504984 | Crossover Study to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab in Healthy Male Volunteers | Samyang Biopharmaceuticals Corporation | Phase 1 | Completed | Healthy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01504984) |
| May 13, 2011 | NCT01353404 | Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg) | Samyang Biopharmaceuticals Corporation | Phase 1 | Completed | Hyperlipidemia | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01353404) |
| April 18, 2011 | NCT01336582 | Pharmacokinetic Study of SYP-0704A and Taxotere to Treat Patient With Advanced Solid Cancer | Samyang Biopharmaceuticals Corporation | Phase 1 | Completed | Solid Tumor | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01336582) |
| January 13, 2011 | NCT01276548 | A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin®... | Samyang Biopharmaceuticals Corporation | Phase 2 | Completed | Ovarian Cancer | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01276548) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 11 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 3 | 3 |
| Phase 4 | 1 |
| Not applicable | 9 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 17 |
| Unknown | 8 |
| Recruiting | 2 |
| Terminated | 2 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Breast Neoplasms | 3 |
| Ovarian Neoplasms | 3 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Prostatic Neoplasms | 1 |
| Head and Neck Neoplasms | 1 |
| Stomach Neoplasms | 1 |
| Esophageal Neoplasms | 1 |
| Hernia, Inguinal | 1 |
| Hyperlipidemias | 1 |
| Pancreatic Neoplasms | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Peripheral Nerve Injuries | 1 |
| Neuralgia, Postherpetic | 1 |
| Pelvic Organ Prolapse | 1 |
| Non-Muscle Invasive Bladder Neoplasms | 1 |
| Carcinoma, Transitional Cell | 1 |
| Recurrence | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Acupuncture clinics in the United States](https://specstream.ai/data/businesses/acupuncture-clinics/united-states)
- [Wholesale florists in the United States](https://specstream.ai/data/businesses/wholesale-florists/united-states)
- [Vocational and technical schools in the United States](https://specstream.ai/data/businesses/vocational-and-technical-schools/united-states)
- [Ukrainian restaurants in the United States](https://specstream.ai/data/businesses/ukrainian-restaurants/united-states)
- [Tower communication companies in the United States](https://specstream.ai/data/businesses/tower-communication-companies/united-states)
- [Tea wholesalers in the United States](https://specstream.ai/data/businesses/tea-wholesalers/united-states)
